Ballicules.com

Lamivudine

EPIVIR

What it isCytidine-analog reverse-transcriptase inhibitor; HIV and chronic hepatitis B.

Why this oneIts signature HIV-resistance mutation develops quickly but impairs viral fitness, so the drug may remain useful in a failing regimen.

What limits itStopping can trigger a severe hepatitis B flare; resistance emerges quickly when it is used alone for hepatitis B.

FDA-approved for

FDA label

BOXED WARNING Severe acute exacerbations of hepatitis B after discontinuation (monitor hepatic function); HIV-1 resistance may emerge if used in unrecognized/untreated HIV-1 (subtherapeutic dose) — offer HIV testing.
FDA dosingPopulationStartTargetMax
Chronic hepatitis BAdults100 mg QD100 mg QD100 mg QD
Chronic hepatitis BPediatric 2-17 yr3 mg/kg QD (max 100 mg)3 mg/kg QD (max 100 mg)100 mg QD

Renal Adjust by CrCl: 30-49 mL/min 100 mg first dose then 50 mg QD; 15-29 100 mg then 25 mg QD; 5-14 35 mg then 15 mg QD; <5 35 mg then 10 mg QD

Hepatic Undefined

Instructions

Cautions

Adverse reactions

Pregnancy APR data show no substantial difference in major birth defects vs background; pregnancy registry available

Lactation Present in human milk; weigh benefits of breastfeeding against maternal need

⚠ BOXED WARNING

Cost, est. cash$10–$500/month

Generic entry2011

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryUnknown / historical label unavailable

Defining liabilityAgent-specific renal, hepatic, hematologic, metabolic and drug-interaction toxicity.

Mechanism of action: Lamivudine ballicule

Lamivudine ballicule: receptor binding, kinetics and half-life diagram

Open Lamivudine in the interactive console ↗